SimplicityBio will apply its expertise in the frame of this €3.2 million research program, the consortium will develop an innovative in vitro diagnostic (IVD) test to assess the risk of developing heart failure (HF) after acute myocardial infarction (AMI). The test will be based on a unique profile of long noncoding RNAs (lncRNA).
SimplicityBio was selected to present in the Next Generation track at the BIO Europe Spring 2017. Drop by or schedule a 1-to-1 meeting. Barcelona, Spain. March 20-22, 2017.
TAmiRNA and SimplicityBio, a Swiss bioinformatics company specialized in in silico biomarker discovery, signed a partnership agreement. The aim of this partnership is to accelerate TAmiRNA´s biomarker development programs and to offer compelling biomarker development services to clients from academia and biotech industry.
IMD is a top business school based in Switzerland, ranked top 3 worldwide in executive education for 5 years in a row now. SimplicityBio will collaborate with the EMBA class and travel to Silicon Valley in 2017.
SimplicityBio was selected by Johnson & Johnson Innovation to present at BIO Europe. Drop by or schedule a 1-to-1 meeting. Cologne, Germany. November 7-9, 2016.
Biomarker Discovery, complete solutions.
TATAA Biocenter has partnered with SimplicityBio to offer complete solutions for biomarker discovery, signature optimization and validation. The partnership offers a complete solution comprising biomarker discovery, assay and protocol optimization, analytical validation, standardization, and clinical validation leading to robust and reliable biomarker signatures for diagnostics, prognostics and theranostics. Platforms include microarrays, qPCR, dPCR and NGS and virtually any kind of biomarkers with emphasis on mRNA, microRNA, lncRNA, DNA (SNP, CNV, methylation, cfDNA), protein and circulating tumor cells.
SimplicityBio was selected to pitch in front of investors at the Swiss Startup Day. Drop by or schedule a 1-to-1 meeting. Bern, Switzerland. October 25, 2016.
Minomic’s poster presents the Multivariate Index Analyte (MIA) Assays for Differentiating Aggressive from Non-Aggressive Prostate Cancer at the First Global Summit on Precision Diagnosis for Prostate Cancer in Boston, USA.
SimplicityBio has a Swiss Patent Pending on its technology and methods. For more information please contact us.
Our client Cellipse has published a peer-reviewed article in AACR’s “The Journal of Cancer Research”, 1 June 2016 Edition.
SimplicityBio was selected as one of the most 500 promising early-stage tech start-up and attended the Pioneers Festival, meeting with prospects and investors. May 23 - 25. Vienna, Austria.
SimplicityBio will be presenting at the BIO Europe. Drop by or schedule a 1-to-1 meeting. Stockholm, Sweden. April 4-6, 2016.
Meet SimplicityBio at the START Summit. St. Gallen, Switzerland. March 18-19, 2016.
SimplicityBio will be attending the 3rd Austrian Biomarker Symposium 2016. Vienna, Austria. March 10-11, 2016.
SimplicityBio is proud to be a sponsor of the 11th Annual Biomarkers Congress in Manchester, UK, February 25-26, 2016. Looking forward to meeting you there.
Meet SimplicityBio in Munich, Germany. November 2-4, 2015.
SimplicityBio is proud to be a gold sponsor of the Biomarker Summit Europe 2015 in Berlin, Germany, October 5-8, 2015. Meet us there.
SimplicityBio has been invited to the Meeting of Experts on Biomarkers to Discriminate Bacterial from other Infectious Causes of Acute Fever, in Geneva, Switzerland. September 22-23 2015.
Meet SimplicityBio at the Nordic Life Science Days in Stockholm, Sweden. September 9-10, 2015.
Meet SimplicityBio in Philadelphia, PA, USA. June 15-18, 2015.
Our CEO, Miguel Barreto, and CSO, Matthew Hall, will be going to Boston and New York with the goal of business development. June, 2015.
2014-2017 © SimplicityBio. ALL Rights Reserved.